Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.

Health technology assessment (Winchester, England)

Volumn 15 Suppl 1, Issue , 2011, Pages 61-67

  Hoyle, M ^a   Crathorne, L ^b   Garside, R ^b   Hyde, C ^b  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLUDARABINE; MONOCLONAL ANTIBODY; OFATUMUMAB; VIDARABINE;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; HUMAN; MORTALITY; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; QUALITY-ADJUSTED LIFE YEARS; VIDARABINE;

MLCS; MLOWN;

EID: 84886942989     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15suppl1/07     Document Type: Review

References (0)